Paving the way for pharma R&D to use FAIR data
The use of FAIR (Findable, Accessible, Interoperable and Reusable) data in drug discovery and development could be transformational. But the pharma industry has been slow to embrace FAIR data — partially because of difficulties in establishing the necessary infrastructure and because of internal culture.
Read this white paper to discover:
- The importance of moving from disconnected datasets to relevant and complementary data
- Reasons for the slow implementation of FAIR principles in pharmaceutical R&D
- Why investing in the right people and approaches is key to the FAIRification of data
If you’d like to learn more about what it will take to realize the promise of FAIR Data in pharmaceutical research and development, please fill out this form and we’ll send you the white paper.